View clinical trials related to Intestinal Malabsorption.
Filter by:To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants<3rd percentile* born at 26-32 weeks GA.
The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.